Rapport Therapeutics Overview
Latest ROE for Rapport Therapeutics: -22.75% — see history and peer comparisons.
Get informed when a big investor buys or sells
+ Follow-22.75%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
Rapport Therapeutics's return on equity stands at -22.75%. That is below the sector sector average of -4.47%. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.
Rapport Therapeutics sits lower the its sector benchmark (-4.47%) with a ROE of -22.75%. That is roughly 409.2% below the sector mean. Peer context matters because what looks expensive or cheap in absolute terms can be normal for the sector.
A ROE of -22.75% for Rapport Therapeutics means each unit of related capital or sales is generating that return rate. Higher is usually better for profitability metrics, but extremely high figures can reflect one-time items or thin equity bases. Review several years of data on this page before extrapolating.
The history chart shows how Rapport Therapeutics's ROE evolved across reporting periods, while the comparison chart places RAPP next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.
